The History of Frontage Laboratories
2024
Frontage Laboratories acquires Accelera S.r.l.’s Bioanalytical and DMPK Businesses in Milan, Italy.
2023
Frontage is proud to once again be named a 2023 CRO Leadership Awards recipient by the Clinical Leader and Life Science Leader magazines, receiving five awards across all categories including Capabilities, Compatibility, Expertise, Quality, and Reliability.
In the Compatibility category, Frontage was recognized as a CRO Leadership Award Champion.
2023
Frontage Laboratories completes acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. in Toronto, Canada.
2022
Frontage Laboratories named a 2022 CRO Leadership Awards recipient by the Clinical Leader and Life Science Leader magazines in all five categories for Quality, Expertise, Reliability, Capabilities, and Compatibility
2022
Acquired Experimur Toxicology and Testing services in Chicago, IL.
Opened 200,000 square foot facility for DMPK and S&T in Suzhou, China.
2021
Acquired Ocean Ridge Biosciences in Deerfield, Florida.
Focused Genomics and RNA and protein-based biomarker discovery services including circulating small RNA, exosome characterization, microbiome RNA and DNA sequencing, multiplex, immunoassays, and DNA polymorphism analysis.
2021
Frontage Clinical Services aquires RAD license to conduct C14 hAME studies.
Acquired additional 71,000 square feet to expand biologics, CMC and central lab services.
2020
Frontage Labs aquires 215,000 square feet lab facility to expand DMPK and Pre-Clinical toxicology servies in Suzhou, China.
2020
DMPK expands to include QWBA center of excellence.
Acquired ACME Biosciences Discovery Services in Palo Alto, California and Shanghai, China. Expands synthetic & medical chemistry and process research & development services.
Expands CMC services in Suzhou, China.
2020
Expanded DMPK through acquisition of Biotranex in Monmouth Junction, New Jersey.
Offers a variety of services to study transporter properties of new chemical entities such as mono- or bi-directional permeability determination in CACO-2, MDCK and P-gp- and BCRP-transfected cell lines; transporter phenotyping/inhibition (IC50 or Ki) and hepatic uptake in hepatocytes from humans and pre-clinical species.
2019
Frontage Clinical Services in Secaucus, New Jersey retools to include tobacco studies.
2019
Expanded DMPK through acquisition of BRI in Vancouver, Canada.
Added Bioanalytical assays for measurement of drug candidates, metabolites and biomarkers, in-vitro drug metabolism,/ADME, in vivo DMPK/ADME, formulation development, DS/DP stability and analytical CMC assays, and anticancer drug pharmacology assesment.
2019
Expanded DMPK through acquisition of RMI in North Wales, Pennsylvania.
Added Metabolite ID/Profiling services, the operation also conducts other metabolism-related studies including but not limited to discovery bioanalytical (small and large molecules), metabolic stability, CYP/UGT phenotyping and inhibition studies.
2019
Frontage Holdings opens new 42,000 square feet lab facility in shanghai, China.
2019
Frontage Labs expanded space for Bioanalytical and CMC services to 85,000 square feet.
Extension of their US bioanalytical laboratories in Exton, PA includes an additional 10,000 square feet laboratory space that will be dedicated to further enhancement of their capabilities in biologic drug development, biomarkers and cell and gene therapy.
2019
Frontage Holdings Corporation celebrates a successful IPO (Initial Public Offering) on the HKEx (Hong Kong Stock Exchange).
2018
Concord Biosciences Preclinical and Agrochemical aquired in Ohio
2018
Dr. Song Li, founder and CEO of Frontage Laboratories Inc., awarded the Healthcare CEO of the Year Enterprise Award for 2018.
2018
In 2018, Data Management and Biostatics expanded to Princeton, New Jersey.
2015
In 2015, Frontage Labs aquires Data Management and Biostatistics services.
Relocated Phase 1 clinical operations to Secaucus, New Jersey with 36,000 square feet and 160 beds.
2014
In 2014, Frontage Labs enters strategic investment with Tigermed.
Additionally expands 10,000 square feet of Bioanalytical labs in Suzhou, China.
2012
In 2012, Frontage Labs expanded by adding DMPK services and relocating Headquarters to Exton, Pennsylvania.
Opened up CMC facility in Suzhou, China.
2008
In 2008, Frontage Lab acquired Phase 1 Clinical Operations in Hackensack, New Jersey with 72 beds.
2007
In 2007, CMC operations were opened at 75 East Uwchian in Exton, Pennsylvania.
2006
In 2006, Frontage Labs opened their first GLP bioanalytical lab in Shanghai totalling 16,000 square feet.
2004
In 2004, Frontage Labs was incorporated and laboratory facilities opened in Pennsylvania.
2002
In 2002, Frontage Labs expanded to include Bioanalytical and CMC (Chemistry, Manufacturing, and Control).
2001
Frontage Labs founded by Dr. Song Li.
Dr. Li first set up a testing laboratory in Thorofare, NJ with a focus on analytical and bioanalytical testing and quickly established a reputation for expertise.
